Literature DB >> 16968393

Agreement of anti-neutrophil cytoplasmic antibody measurements obtained from serum and plasma.

A S Lee1, J D Finkielman, T Peikert, A M Hummel, M A Viss, G L Jacob, H A Homburger, U Specks.   

Abstract

Serum and plasma are used interchangeably to measure anti-neutrophil cytoplasmic antibodies (ANCA), even though the release of ANCA target antigens during the preparation of serum could affect ANCA assays and cause discrepancies between the results obtained from serum and plasma. To what extent ANCA test results obtained from serum agree and correlate with results from plasma remains unknown. Therefore, a comprehensive comparison was performed using serum and plasma samples which were collected in 175 patients with active Wegener's granulomatosis at enrollment of a recent randomized trial. These paired serum and plasma samples were subjected to parallel ANCA testing by standard indirect immunofluorescence on ethanol-fixed neutrophils, a direct enzyme-linked immunoassay (ELISA) for proteinase 3 (PR3)-ANCA and myeloperoxidase (MPO)-ANCA, and two different capture ELISAs for PR3-ANCA. The concordance of categorical serum and plasma ANCA results was assessed using kappa-coefficients. These were > 0.8 for all assays, indicating a very good concordance between positive and negative serum and plasma results. Spearman's correlation coefficients for serum and plasma PR3-ANCA values obtained by direct ELISA and both capture ELISAs were > or = 0.95 (P < 0.0001). Our study shows that serum and plasma samples can be used interchangeably for measuring ANCA.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16968393      PMCID: PMC1809725          DOI: 10.1111/j.1365-2249.2006.03179.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  20 in total

1.  Should soluble CD40 ligand be measured from serum or plasma samples?

Authors:  Dániel Bereczki; Emõke Nagy; András Pál; Mária T Magyar; József Balla
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-06-01       Impact factor: 8.311

2.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

3.  Leukocyte elastase release during blood coagulation. A potential mechanism for activation of the alternative fibrinolytic pathway.

Authors:  E F Plow
Journal:  J Clin Invest       Date:  1982-03       Impact factor: 14.808

Review 4.  International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA)

Authors:  J Savige; D Gillis; E Benson; D Davies; V Esnault; R J Falk; E C Hagen; D Jayne; J C Jennette; B Paspaliaris; W Pollock; C Pusey; C O Savage; R Silvestrini; F van der Woude; J Wieslander; A Wiik
Journal:  Am J Clin Pathol       Date:  1999-04       Impact factor: 2.493

5.  A novel capture-ELISA for detection of anti-neutrophil cytoplasmic antibodies (ANCA) based on c-myc peptide recognition in carboxy-terminally tagged recombinant neutrophil serine proteases.

Authors:  Augustine S Lee; Javier D Finkielman; Tobias Peikert; Amber M Hummel; Margaret A Viss; Ulrich Specks
Journal:  J Immunol Methods       Date:  2005-10-03       Impact factor: 2.303

6.  Etanercept plus standard therapy for Wegener's granulomatosis.

Authors: 
Journal:  N Engl J Med       Date:  2005-01-27       Impact factor: 91.245

7.  Detection of anti-neutrophil cytoplasmic antibodies under actual clinical testing conditions.

Authors:  Kimberly A Russell; Elaine Wiegert; Darrell R Schroeder; Henry A Homburger; Ulrich Specks
Journal:  Clin Immunol       Date:  2002-05       Impact factor: 3.969

8.  The binding of proteinase 3 antineutrophil cytoplasmic antibodies (PR3-ANCA) varies in different ELISAs.

Authors:  M Trevisin; P Neeson; J Savige
Journal:  J Clin Pathol       Date:  2004-03       Impact factor: 3.411

9.  Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener's granulomatosis: first results from a multicentre study.

Authors:  Elena Csernok; Julia Holle; Bernhard Hellmich; Jan Willem; Cohen Tervaert; Cees G M Kallenberg; Peter C Limburg; John Niles; Gouli Pan; Ulrich Specks; Kerstin Westman; Jörgen Wieslander; Kirsten De Groot; Wolfgang L Gross
Journal:  Rheumatology (Oxford)       Date:  2003-10-29       Impact factor: 7.580

10.  Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial.

Authors:  John H Stone
Journal:  Arthritis Rheum       Date:  2003-08
View more
  3 in total

1.  Discrimination and variable impact of ANCA binding to different surface epitopes on proteinase 3, the Wegener's autoantigen.

Authors:  Francisco Silva; Amber M Hummel; Dieter E Jenne; Ulrich Specks
Journal:  J Autoimmun       Date:  2010-12       Impact factor: 7.094

Review 2.  Antineutrophil cytoplasmic autoantibodies: how should the biologist manage them?

Authors:  C Beauvillain; Y Delneste; G Renier; P Jeannin; J F Subra; A Chevailler
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

Review 3.  An approach to the diagnosis and management of systemic vasculitis.

Authors:  A Miller; M Chan; A Wiik; S A Misbah; R A Luqmani
Journal:  Clin Exp Immunol       Date:  2010-01-12       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.